Quick Read – CVS trades at 14x forward earnings despite a 57% 12-month surge, while Pfizer’s 8x multiple and 7.2% yield price in its post-COVID pipeline risks. – Pfizer’s pipeline includes 20 pivotal studies launching in 2026, obesity assets from its $7 billion Metsera…
quisition, and a Lyme vaccine posting 73% efficacy. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn’t make the cut. Grab the names FREE today
Healthcare is quietly becoming the value hunter’s playground of 2026. While the mega cap tech trade keeps sucking up oxygen, two of the largest healthcare names in the S&P 500 are trading at forward multiples that look mispriced against their earnings power. Morningstar’s 2026 outlook flagged US healthcare as one of the few sectors still offering broad value in an otherwise fully priced market, and PineBridge’s 2026 Equity Outlook noted that new pricing agreements with Medicare and Medicaid and a 15% cap on pharmaceutical imports have alleviated the worst tail risks for the sector.
Against that backdrop, CVS and Pfizer both trade well below their earnings-power valuations. One is a legitimate turnaround with a raised guide; the other is a dividend heavyweight rebuilding its pipeline. Here is the case for each in July.